Zoetis Inc. (NYSE:ZTS) Shares Purchased by Bellecapital International Ltd.

Bellecapital International Ltd. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 0.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 53,077 shares of the company’s stock after acquiring an additional 338 shares during the quarter. Zoetis accounts for about 2.1% of Bellecapital International Ltd.’s holdings, making the stock its 15th biggest position. Bellecapital International Ltd.’s holdings in Zoetis were worth $10,370,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in ZTS. Sarasin & Partners LLP boosted its stake in shares of Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after acquiring an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new stake in Zoetis in the first quarter valued at $210,815,000. Marshall Wace LLP increased its position in shares of Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after buying an additional 824,843 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after buying an additional 414,605 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of Zoetis by 178.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 639,352 shares of the company’s stock worth $108,185,000 after buying an additional 409,522 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. BTIG Research lifted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Trading Down 1.9 %

Shares of NYSE ZTS traded down $3.71 during trading on Monday, hitting $189.57. 179,507 shares of the company traded hands, compared to its average volume of 2,515,052. The firm has a market capitalization of $86.50 billion, a P/E ratio of 36.53, a P/E/G ratio of 3.00 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a 50-day moving average price of $188.98 and a 200-day moving average price of $177.17. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.41 earnings per share. On average, equities analysts predict that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.91%. Zoetis’s payout ratio is currently 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.